<DOC>
	<DOCNO>NCT00706030</DOCNO>
	<brief_summary>The purpose study identify high tolerable dose neratinib ( HKI-272 ) combination vinorelbine ass safety combination two drug well obtain preliminary information whether combination two drug effect solid tumor . The study conduct two part . In first part , test do 12 subject determine high tolerable dose HKI-272 vinorelbine patient advance solid tumor . In second part study , approximately 60 additional subject metastatic ErbB-2-positive breast cancer , prior exposure lapatinib ( Tykerb® ) , plan add well define tolerability preliminary activity HKI-272 combination vinorelbine . Up 20 additional subject ErbB-2-positive breast cancer prior lapatinib ( Tykerb® ) exposure also plan enrol part 2 exploratory analysis .</brief_summary>
	<brief_title>Study Evaluating Neratinib ( HKI-272 ) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Confirmed pathologic diagnosis solid tumor curable available therapy HKI272 plus vinorelbine reasonable treatment option ( part 1 ) Confirmed pathologic diagnosis ErbB2positive breast cancer ( current stage IV ) female subject vinorelbine plus HKI272 reasonable treatment option ( part 2 ) . At least 1 prior antineoplastic chemotherapy treatment regimen metastatic disease least 1 prior treatment trastuzumabcontaining regimen least 6 week , metastatic disease subject relapse adjuvant treatment ( part 2 ) . At least 1 measurable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) . More 2 prior antineoplastic treatment regimen ( exclude hormonotherapy ) metastatic disease . Subjects relapse adjuvant treatment n't receive one line chemotherapy metastatic disease ( part 2 ) . Prior treatment vinorelbine metastatic setting , prior treatment ErbB2 target agent except trastuzumab ( part 2 ) . Up 20 subject ErbB2overexpressing metastatic breast cancer previously expose lapatinib refractory lapatinib may enrol part 2 . Prior treatment anthracyclines cumulative dose doxorubicin great 400 mg/m2 , epirubicin dose great 800 mg/m2 , equivalent dose anthracyclines derivative ( part 2 ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Metastatic breast cancer</keyword>
</DOC>